As advances in melanoma treatment continue to improve survival, clinicians are increasingly encountering patients living with the long-term effects of their treatment. But what happens when treatment ends and the side effects persist?

In this episode of Melanoma Insights for Professionals, A/Prof Robyn Saw leads a multidisciplinary discussion to explore the chronic toxicities associated with melanoma treatment, including immunotherapy-related side effects, surgical complications and their impact on patients' physical and psychological wellbeing.

The panel of experts discuss:

• Systemic toxicities: Long-term and potentially irreversible effects of immunotherapy, alongside the common and sometimes persistent side effects of targeted therapy.
• Cutaneous toxicities: Immunotherapy-related skin conditions, chronic itch and rashes, and the importance of early diagnosis and referral.
• Surgical complications: Long-term effects such as scarring, neuralgia and lymphoedema, and strategies for minimising their impact.
• Psychological wellbeing: The emotional challenges of survivorship and the impact of chronic side effects on quality of life.
• Multidisciplinary survivorship care: Co-ordinating ongoing care, managing persistent toxicities and supporting patients beyond active treatment.

The panel also explores emerging approaches to reducing treatment-related morbidity, including treatment de-escalation, and the importance of looking beyond cancer control to consider patients' long-term function, wellbeing and quality of life.

This podcast is suitable for medical oncologists, surgeons, dermatologists, skin cancer doctors, GPs, nurses and other healthcare professionals.

RESOURCES

• MIA Patient Resources
• Cancer Council’s Understanding Immunotherapy Fact Sheet
• MIA's Melanoma Education Portal

REFERENCES

• Haanen J, Obeid M, Spain L, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238.

• Abraham PE, Johnson DB. Long-Term Toxicities of Immune Checkpoint Inhibitors. Drugs. 2025 Dec;85(12):1535-1549

SPEAKERS

• A/Prof Robyn Saw - Surgical Oncologist

Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Faculty Member, Melanoma Institute Australia

• A/Prof Linda Martin - Dermatologist

Director of Dermatologist Services, Melanoma Institute Australia, Staff Specialist in Paediatric Dermatology, Sydney Children’s Hospital | Associate Professor, University of NSW

• Dr Rebecca Symons - Medical Oncologist

Melanoma Institute Australia

• Dr Lisa Gomes - Senior Clinical Psychologist

Melanoma Institute Australia

Please note that this podcast was accurate at the time of recording (October 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

In this episode from MIA’s podcast Melanoma Insights for Professionals, our experts explore the critical role of multidisciplinary collaboration in delivering contemporary melanoma care. Hear how melanoma multidisciplinary teams (MDTs) bring together diverse expertise to navigate increasingly complex treatment pathways, discuss challenging cases and identify opportunities for patients to participate in clinical trials.

The discussion provides insight into how MDTs operate in practice, the value they bring to patient outcomes, and how collaboration between clinicians and researchers continues to drive progress.

The panel also explores why clinical trials remain fundamental to advancing melanoma care, how practice-changing evidence has shaped current standards of treatment, and what emerging developments may define the future of melanoma management.

This podcast is suitable for multidisciplinary specialists, clinical trial researchers and other healthcare professionals.

REFERENCE

• GV Long, et al. A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi). J Clin Oncol 44, 9502-9502(2026).

SPEAKERS

• Prof Alexander van Akkooi - Surgical Oncologist | Melanoma Institute Australia and The University of Sydney

• Prof Georgina Long AO - Medical Oncologist and Medical Director | Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital

• Maria Gonzalez - CEO and former Head of Clinical Trials | Melanoma Institute Australia

Please note that this podcast was accurate at the time of recording (June 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Melanoma Institute Australia’s Education Program⁠ is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

How will melanoma detection change over the next decade?

In this episode from MIA’s podcast Melanoma Insights for Professionals, our multidisciplinary experts explore how targeted screening, personalised risk assessment, advanced imaging, artificial intelligence and evolving models of care could transform the way melanoma is detected.

The discussion provides insight into how we can identify those most likely to benefit from screening, reduce unnecessary biopsies and surveillance, and make better use of Australia’s limited healthcare workforce and resources.

This podcast is suitable for dermatologists, skin cancer doctors, GPs, nurses, public health researchers and other healthcare professionals.

LEARNING OBJECTIVES

• Identify key risk factors for melanoma and describe how risk stratification can be used to inform personalised prevention, skin checks and surveillance.

• Discuss the potential benefits, harms and limitations of targeted melanoma screening and emerging detection technologies, including imaging and artificial intelligence (AI).

• Discuss the implications of evolving melanoma detection strategies for general practice, including workforce requirements, models of care, triage and referral pathways.

REFERENCES AND RESOURCES

• Yan S, Yu Z, Primiero C, Vico-Alonso C, et al. Amultimodal vision foundation model for clinical dermatology. Nat Med. 2025 Aug;31(8):2691-2702.
• Snoswell CL, Caffery LJ, Whitty JA, et al. Cost-effectiveness of Skin Cancer Referraland Consultation Using Teledermoscopy in Australia. JAMA Dermatol. 2018;154(6):694–700.
• MIA's Melanoma Risk Prediction Calculators
• More information on the Roadmap for a National Targeted Melanoma Screening Program.

ACCREDITATION

This podcast has been accredited for 0.5 EA CPD hours in the RACGP and SkinPro CPD Programs. To obtain a Certificate of Completion and have CPD hours uploaded on your behalf, please listen to this podcast via the Melanoma Education Portal (free registration required).

SPEAKERS

Prof Pascale Guitera
Director of the Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital | Professorial Research Fellow, The University of Sydney | Faculty Member, Melanoma Institute Australia

Prof Rachael Morton

Director of Health Economics and Health Technology Assessment, The Sydney Clinical Trials Centre, The University of Sydney | Faculty Member, Melanoma Institute Australia

Prof Victoria Mar

Director of the Victorian Melanoma Service at The Alfred | Professor of DermatoOncology, School of Public Health and Preventive Medicine, Monash University

Dr Amelia Smit
Senior Research Fellow in Cancer Epidemiology , The Daffodil Centre, The University of Sydney and Cancer Council NSW

Please note that this podcast was accurate at the time of recording (September 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.